Clinical trials: Covid19- Coronavirus- Sars-cov-2
Novel COVID-19-Infected Pneumonia
A Study of Jaktinib Hydrochloride Tablets in the Treatment of Severe Novel Coronavirus Pneumonia
A randomized, double-blind, placebo parallel control study and is expected to enroll 20-60 eligible patients with severe novel coronavirus pneumonia.
- Trial name
- COVID-19 (NCT05688839)
- Testing
- Jaktinib hydrochloride tablets
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Covid19
Remotely-conducted Trial of Famotidine vs Placebo for Patients at Home With Coronavirus (COVID) of 2019 (COVID-19)
Kit for reading vital signs (thermometer, wrist blood pressure device, finger oximeter) and with study drug is overnighted to qualified subjects with early symptoms of COVID-19.
- Trial name
- Pepcid4COV19 (NCT04565392)
- Testing
- Famotidine 20 milligram tablet
- Where
- United States
- Sponsor
- drpykessupplements.com
SARS-CoV, SARS-CoV-2
Study of VXCO-100, a SARS-CoV Candidate Vaccine in Healthy Adults in the United States
The purpose of this study is to evaluate the safety and immunogenicity of ascending dose levels of VXCO-100 in healthy adults.
- Trial name
- NCT05870839
- Testing
- VXCO-100
- Where
- 3 sites in United States
- Volunteers
- 121 people, healthy volunteers welcome
- Sponsor
- Vaccine Company, Inc, a wholly owned subsidiary of Eli Lilly and Company
SARS-CoV-2, COVID-19
eVusheld Assessment reaL wORld Effectiveness in the VA Health System
An AstraZeneca-sponsored observational, electronic healthcare record (EHR)-embedded retrospective cohort study to assess the real-world effectiveness of EVUSHELD against SARS-CoV-2 infection, COVID-19-related hospitalization, and…
- Trial name
- VALOR-VA (NCT05663957)
- Testing
- Evusheld
- Where
- United States
- Volunteers
- 5,814 people
- Sponsor
- AstraZeneca
Influenza, Human, Pneumonia, Pneumococcal
Evaluation of Immunogenicity and Safety of Combined Immunization of COVID-19 Vaccine (Produced in Beijing) and PPV23 / IIV4
Subjects will be recruited and divided into 3 groups: Experimental Group (384 subjects): 1st dose : combined vaccination of COVAX+IIV4, 2nd dose: combined vaccination of COVAX+PPV23; Control Group A (384 subjects): 1st dose…
- Conditions
- Influenza, Human, Pneumonia, Pneumococcal, Covid19
- Trial name
- NCT04790851
- Testing
- COVAX+IIV4; COVAX+PPV23, COVAX only (1st and 2nd dose), IIV4 for the 1st dose and PPV23 for the 2nd dose
- Where
- 3 sites in China
- Volunteers
- 1,133 people, healthy volunteers welcome
- Sponsor
- China National Biotec Group Company Limited
COVID-19
Novel Coronavirus Induced Severe Pneumonia Treated by Dental Pulp Mesenchymal Stem Cells
Evaluation of novel coronavirus induced severe pneumonia by dental pulp mesenchymal stem cells
- Trial name
- NCT04302519
- Testing
- Dental pulp mesenchymal stem cells
- Volunteers
- 24 people
- Sponsor
- CAR-T (Shanghai) Biotechnology Co., Ltd.
COVID-19, Influenza A
Prospective Clinical Evaluation of COVID/Flu Detect™ Rapid Self-Test in Symptomatic Subjects for Non-Prescription Over-the-Counter (OTC) Use
The goal of this study is to evaluate the performance of the COVID/Flu Detect™ Rapid Self-Test when used in a home-like setting by lay users.
- Conditions
- COVID-19, Influenza A, Influenza B
- Trial name
- NCT06734741
- Testing
- COVID/Flu Detect™ Rapid Self-Test
- Where
- 10 sites in United States
- Volunteers
- 899 people
- Sponsor
- InBios International, Inc.
Critical Confirmed Coronavirus Disease (COVID)-19
A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19
The purpose of this study is to evaluate the clinical response of sirukumab (administered as a single intravenous dose) plus standard of care (SOC) compared to placebo plus SOC in COVID-19.
- Trial name
- NCT04380961
- Testing
- Sirukumab, Standard of Care (SOC)
- Where
- 16 sites in United States
- Volunteers
- 212 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Healthy Volunteers
A Trial to Learn if Different Doses of REGN17092 Are Safe in Healthy Adults
The purpose of this study is to learn about the safety and tolerability of different doses of REGN17092 administered with a needle either under the skin (called "subcutaneous") or into a vein (called an "infusion") in healthy…
- Trial name
- NCT05923424
- Testing
- REGN17092
- Where
- Belgium
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Regeneron Pharmaceuticals
SARS-CoV-2 Infection
Halodine Nasal Antiseptic in Patients With COVID-19
Povidone iodine (PVP-I) is a well-known broad spectrum, resistance free antimicrobial agent that has a long history of safe and effective use.
- Trial name
- NCT04517188
- Testing
- Povidone-Iodine Solution 1.25% w/w [0.125% available iodine] USP
- Volunteers
- 40 people
- Sponsor
- Halodine LLC
COVID-19
Detection of COVID-19 Using Breath Analysis - Validation Study.
Detection of the 2019 novel Coronavirus (SARS-CoV-2) using breath analysis - Validation study.
- Trial name
- NCT05224622
- Testing
- VOX
- Where
- Israel
- Volunteers
- 192 people, healthy volunteers welcome
- Sponsor
- Scentech Medical Technologies Ltd
SARS-CoV 2, COVID
In-vitro Diagnostic Test to Predict COVID-19 Mortality and Disease Severity
The COVID-19 Androgen Sensitivity Test is a non-invasive In-Vitro Diagnostic device that utilizes Next Generation Sequencing Technology (NGS).
- Conditions
- SARS-CoV 2, COVID, COVID-19, Androgenetic Alopecia
- Trial name
- NCT04368897
- Testing
- CAG length <22, CAG length >=22
- Where
- Spain
- Sponsor
- Applied Biology, Inc.
Coronavirus, COVID
A Phase 2 Study to Evaluate Axatilimab for Hospitalized Participants With Respiratory Involvement Secondary to COVID-19
This was a randomized, double-blind, placebo-controlled, 29-day study to assess the efficacy and safety of axatilimab plus standard of care (SOC), compared with placebo plus SOC, in participants with respiratory signs and…
- Conditions
- Coronavirus, COVID, ARDS, Cytokine Storm
- Trial name
- NCT04415073
- Testing
- SNDX-6352
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- Syndax Pharmaceuticals
COVID-19, SARS-CoV-2
Safety and Immunogenicity Study of a Booster Dose of the Investigational CV0501 mRNA COVID-19 Vaccine in Adults at Least 18 Years Old
Prevention of COVID-19 caused by SARS-CoV-2.
- Trial name
- NCT05477186
- Testing
- CV0501 (3 μg), CV0501 (6 μg), CV0501 (12 μg)
- Where
- 17 sites in United States, Australia and 1 more
- Volunteers
- 185 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
COVID-19, COVID-19 Pandemic
Prospective Study to Validate the Diagnostic Performance of IVD CAPSULE COVID-19-NP Test for the Detection of SARS-CoV-2
The purpose of the study is to conduct a prospective evaluation of the diagnostic performance of the IVD CAPSULE COVID-19-NP test for antigenic determination of SARS-CoV-2 virus on the abioSCOPE® instrument.
- Trial name
- NCT05596032
- Where
- Italy
- Volunteers
- 440 people
- Sponsor
- Abionic SA
Viral Disease
First-In-Human Study To Evaluate Safety, Tolerability, And Pharmacokinetics Following Single Ascending And Multiple Ascending Doses of PF-07304814 In Hospitalized Participants With COVID-19.
It is Phase 1b, 2-part, double-blind, placebo-controlled study to evaluate safety, tolerability, and pharmacokinetics of PF-07304814, in patients hospitalized with SARS-CoV-2 virus infection.
- Trial name
- NCT04535167
- Testing
- PF-07304814
- Where
- 13 sites in United States, Belgium and 2 more
- Volunteers
- 26 people
- Sponsor
- Pfizer
Covid19, SARS CoV 2 Infection
Safety and Immunogenicity Study of Recombinant Protein RBD Candidate Vaccine Against SARS-CoV-2 in Adult Healthy Volunteers (COVID-19)
This is a first-in-human, phase I/IIa, randomized, controlled, observer-blinded, dose-escalation, multicentre clinical trial to evaluate safety and immunogenicity of COVID-19 HIPRA vaccine in adult healthy volunteers.
- Trial name
- NCT05007509
- Testing
- COVID-19 vaccine HIPRA 10, COVID-19 vaccine HIPRA 20, COVID-19 vaccine HIPRA 40
- Where
- 2 sites in Spain
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Laboratorios Hipra, S.A.
Prevention of COVID-19
ZF2001 Booster Immunization Clinical Trials of 6 Months After the Completion of Basic Immunization
The purpose of this study is to evaluate the immunogenicity and safety of the recombinant novel coronavirus vaccine (CHO cells) after the booster immunization.
- Trial name
- NCT05198063
- Testing
- Recombinant novel coronavirus vaccine (CHO cells)
- Where
- China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Healthy Volunteers
Safety and Immunogenicity of AdCOVID in Healthy Adults (COVID-19 Vaccine Study)
A study to evaluate the immune response and safety of AdCOVID administered as an intranasal spray in healthy adults.
- Trial name
- NCT04679909
- Testing
- AdCOVID
- Where
- 6 sites in United States
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- Altimmune, Inc.
COVID-19
To Evaluate the Immunogenicity and Safety of Sequential Booster Immunization of Recombinant Novel Coronavirus Vaccine (CHO Cells) for SARS-CoV-2
An open experimental design was used in this study, and 240 subjects were planned to be enrolled. To evaluate the immunogenicity and safety of recombinant Novel Coronavirus vaccine (CHO cells) after sequential intensification in…
- Trial name
- NCT05895110
- Testing
- Recombinant Novel Coronavirus vaccine (CHO Cells)
- Where
- China
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.